Showing 109 results
-
Media Release /Ontario is the first province in Canada to offer public reimbursement for Pluvicto™, a targeted radioligand therapy for patients with progressive PSMA-positive metastatic castration-resistant…
-
Webform /Novartis Canada is deeply committed to providing support to organizations that deliver real benefits to our communities and beyond. To this end, we are implementing new guiding principles to…
-
Media Release /Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancerMontreal, Quebec, December 13, 2024 –…
-
Media Release /The Novartis Health Equity Initiative was launched earlier this year as a call for ideas to help tackle persistent health disparities and promote equal access to healthcare in CanadaSubmissions were…
-
Media Release /Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a…
-
Story / -
Story /
